TD Cowen raised the firm’s price target on Natera (NTRA) to $280 from $240 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Exelixis, Natera announce collaboration on STELLAR-316 trial
- Natera initiated with a Buy at Citi
- Natera: Leading MRD Position, Expanding Margins, and Premium Valuation Support Buy Rating and $300 Target
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU
- Natera management to meet with Piper Sandler